Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China

Bao Chu Zhang, Yuan Rong Zhu, Jin Bing Wang, Yan Wu, Qi Nan Zhang, Geng Sun Qian, Shuang Yuan Kuang, Yan Feng Li, Xi Fang, Lu Yi Yu, Silvio De Flora, Lisa Paula Jacobson, Audrey Zarba, Patricia Egner, Xia He, Jia Sheng Wang, Baibai Chen, Cheryl L. Enger, Nancy E. Davidson, Gary B. Gordon & 6 others Mary B. Gorman, Hans J. Prochaska, John Davis Groopman, Alvaro Munoz, Kathy J. Helzlsouer, Thomas W Kensler

Research output: Contribution to journalArticle

Abstract

Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. This chemopreventive action of oltipraz results primarily from an altered balance in aflatoxin metabolic activation and detoxication. In 1995, a randomized, placebo-controlled, double-blind intervention was conducted in residents of Qidong, People's Republic of China, who are at high risk for exposure to aflatoxin and development of hepatocellular carcinoma. The major study objectives were to define a dose and schedule for oltipraz that would reduce levels of aflatoxin biomarkers in biofluids of the participants, and to further characterize dose-limiting side effects. Two hundred thirty-four healthy eligible individuals, including those infected with HBV, were randomized to receive either 125 mg oltipraz daily, 500 mg oltipraz weekly, or placebo. Blood and urine specimens were collected to monitor potential toxicities and evaluate biomarkers over the 8- week intervention and subsequent 8-week follow-up periods. Overall, compliance in the intervention was excellent; approximately 85% of the participants completed the study. Objective evaluation of adverse events was greatly facilitated by inclusion of a placebo arm in the study design. A syndrome involving numbness, tingling, and pain in the fingertips was the only event that occurred more frequently among the active groups (18 and 14% of the daily 125 mg and weekly 500 mg arms, respectively) compared to placebo (3%). These symptoms were reversible and could be relieved with non-steroidal antiinflammatory agents. A more complete understanding of the chemopreventive utility of oltipraz awaits completion of an assessment of the efficacy of oltipraz in modulating levels of aflatoxin biomarkers.

Original languageEnglish (US)
Pages (from-to)166-173
Number of pages8
JournalJournal of Cellular Biochemistry
Volume67
Issue numberSUPPL. 28/29
StatePublished - 1997

Fingerprint

Chemoprevention
Aflatoxins
China
Biomarkers
Placebos
Schistosomicides
Hypesthesia
Non-Steroidal Anti-Inflammatory Agents
oltipraz
Compliance
Toxicity
Rats
Hepatocellular Carcinoma
Appointments and Schedules
Blood
Chemical activation
Urine
Pain

Keywords

  • Aflatoxin albumin adducts
  • Aflatoxin B
  • Biomarkers
  • Enzyme induction
  • Glutathione S-transferases
  • Hepatocellular carcinoma

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Zhang, B. C., Zhu, Y. R., Wang, J. B., Wu, Y., Zhang, Q. N., Qian, G. S., ... Kensler, T. W. (1997). Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China. Journal of Cellular Biochemistry, 67(SUPPL. 28/29), 166-173.

Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China. / Zhang, Bao Chu; Zhu, Yuan Rong; Wang, Jin Bing; Wu, Yan; Zhang, Qi Nan; Qian, Geng Sun; Kuang, Shuang Yuan; Li, Yan Feng; Fang, Xi; Yu, Lu Yi; De Flora, Silvio; Jacobson, Lisa Paula; Zarba, Audrey; Egner, Patricia; He, Xia; Wang, Jia Sheng; Chen, Baibai; Enger, Cheryl L.; Davidson, Nancy E.; Gordon, Gary B.; Gorman, Mary B.; Prochaska, Hans J.; Groopman, John Davis; Munoz, Alvaro; Helzlsouer, Kathy J.; Kensler, Thomas W.

In: Journal of Cellular Biochemistry, Vol. 67, No. SUPPL. 28/29, 1997, p. 166-173.

Research output: Contribution to journalArticle

Zhang, BC, Zhu, YR, Wang, JB, Wu, Y, Zhang, QN, Qian, GS, Kuang, SY, Li, YF, Fang, X, Yu, LY, De Flora, S, Jacobson, LP, Zarba, A, Egner, P, He, X, Wang, JS, Chen, B, Enger, CL, Davidson, NE, Gordon, GB, Gorman, MB, Prochaska, HJ, Groopman, JD, Munoz, A, Helzlsouer, KJ & Kensler, TW 1997, 'Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China', Journal of Cellular Biochemistry, vol. 67, no. SUPPL. 28/29, pp. 166-173.
Zhang BC, Zhu YR, Wang JB, Wu Y, Zhang QN, Qian GS et al. Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China. Journal of Cellular Biochemistry. 1997;67(SUPPL. 28/29):166-173.
Zhang, Bao Chu ; Zhu, Yuan Rong ; Wang, Jin Bing ; Wu, Yan ; Zhang, Qi Nan ; Qian, Geng Sun ; Kuang, Shuang Yuan ; Li, Yan Feng ; Fang, Xi ; Yu, Lu Yi ; De Flora, Silvio ; Jacobson, Lisa Paula ; Zarba, Audrey ; Egner, Patricia ; He, Xia ; Wang, Jia Sheng ; Chen, Baibai ; Enger, Cheryl L. ; Davidson, Nancy E. ; Gordon, Gary B. ; Gorman, Mary B. ; Prochaska, Hans J. ; Groopman, John Davis ; Munoz, Alvaro ; Helzlsouer, Kathy J. ; Kensler, Thomas W. / Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China. In: Journal of Cellular Biochemistry. 1997 ; Vol. 67, No. SUPPL. 28/29. pp. 166-173.
@article{0c505dc84c16457b85882b0b17163e05,
title = "Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China",
abstract = "Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. This chemopreventive action of oltipraz results primarily from an altered balance in aflatoxin metabolic activation and detoxication. In 1995, a randomized, placebo-controlled, double-blind intervention was conducted in residents of Qidong, People's Republic of China, who are at high risk for exposure to aflatoxin and development of hepatocellular carcinoma. The major study objectives were to define a dose and schedule for oltipraz that would reduce levels of aflatoxin biomarkers in biofluids of the participants, and to further characterize dose-limiting side effects. Two hundred thirty-four healthy eligible individuals, including those infected with HBV, were randomized to receive either 125 mg oltipraz daily, 500 mg oltipraz weekly, or placebo. Blood and urine specimens were collected to monitor potential toxicities and evaluate biomarkers over the 8- week intervention and subsequent 8-week follow-up periods. Overall, compliance in the intervention was excellent; approximately 85{\%} of the participants completed the study. Objective evaluation of adverse events was greatly facilitated by inclusion of a placebo arm in the study design. A syndrome involving numbness, tingling, and pain in the fingertips was the only event that occurred more frequently among the active groups (18 and 14{\%} of the daily 125 mg and weekly 500 mg arms, respectively) compared to placebo (3{\%}). These symptoms were reversible and could be relieved with non-steroidal antiinflammatory agents. A more complete understanding of the chemopreventive utility of oltipraz awaits completion of an assessment of the efficacy of oltipraz in modulating levels of aflatoxin biomarkers.",
keywords = "Aflatoxin albumin adducts, Aflatoxin B, Biomarkers, Enzyme induction, Glutathione S-transferases, Hepatocellular carcinoma",
author = "Zhang, {Bao Chu} and Zhu, {Yuan Rong} and Wang, {Jin Bing} and Yan Wu and Zhang, {Qi Nan} and Qian, {Geng Sun} and Kuang, {Shuang Yuan} and Li, {Yan Feng} and Xi Fang and Yu, {Lu Yi} and {De Flora}, Silvio and Jacobson, {Lisa Paula} and Audrey Zarba and Patricia Egner and Xia He and Wang, {Jia Sheng} and Baibai Chen and Enger, {Cheryl L.} and Davidson, {Nancy E.} and Gordon, {Gary B.} and Gorman, {Mary B.} and Prochaska, {Hans J.} and Groopman, {John Davis} and Alvaro Munoz and Helzlsouer, {Kathy J.} and Kensler, {Thomas W}",
year = "1997",
language = "English (US)",
volume = "67",
pages = "166--173",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 28/29",

}

TY - JOUR

T1 - Oltipraz chemoprevention trial in Qidong, Jiangsu province, People's Republic of China

AU - Zhang, Bao Chu

AU - Zhu, Yuan Rong

AU - Wang, Jin Bing

AU - Wu, Yan

AU - Zhang, Qi Nan

AU - Qian, Geng Sun

AU - Kuang, Shuang Yuan

AU - Li, Yan Feng

AU - Fang, Xi

AU - Yu, Lu Yi

AU - De Flora, Silvio

AU - Jacobson, Lisa Paula

AU - Zarba, Audrey

AU - Egner, Patricia

AU - He, Xia

AU - Wang, Jia Sheng

AU - Chen, Baibai

AU - Enger, Cheryl L.

AU - Davidson, Nancy E.

AU - Gordon, Gary B.

AU - Gorman, Mary B.

AU - Prochaska, Hans J.

AU - Groopman, John Davis

AU - Munoz, Alvaro

AU - Helzlsouer, Kathy J.

AU - Kensler, Thomas W

PY - 1997

Y1 - 1997

N2 - Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. This chemopreventive action of oltipraz results primarily from an altered balance in aflatoxin metabolic activation and detoxication. In 1995, a randomized, placebo-controlled, double-blind intervention was conducted in residents of Qidong, People's Republic of China, who are at high risk for exposure to aflatoxin and development of hepatocellular carcinoma. The major study objectives were to define a dose and schedule for oltipraz that would reduce levels of aflatoxin biomarkers in biofluids of the participants, and to further characterize dose-limiting side effects. Two hundred thirty-four healthy eligible individuals, including those infected with HBV, were randomized to receive either 125 mg oltipraz daily, 500 mg oltipraz weekly, or placebo. Blood and urine specimens were collected to monitor potential toxicities and evaluate biomarkers over the 8- week intervention and subsequent 8-week follow-up periods. Overall, compliance in the intervention was excellent; approximately 85% of the participants completed the study. Objective evaluation of adverse events was greatly facilitated by inclusion of a placebo arm in the study design. A syndrome involving numbness, tingling, and pain in the fingertips was the only event that occurred more frequently among the active groups (18 and 14% of the daily 125 mg and weekly 500 mg arms, respectively) compared to placebo (3%). These symptoms were reversible and could be relieved with non-steroidal antiinflammatory agents. A more complete understanding of the chemopreventive utility of oltipraz awaits completion of an assessment of the efficacy of oltipraz in modulating levels of aflatoxin biomarkers.

AB - Oltipraz has been used clinically in many regions of the world as an antischistosomal agent and is an effective inhibitor of aflatoxin hepatocarcinogenesis in rats. This chemopreventive action of oltipraz results primarily from an altered balance in aflatoxin metabolic activation and detoxication. In 1995, a randomized, placebo-controlled, double-blind intervention was conducted in residents of Qidong, People's Republic of China, who are at high risk for exposure to aflatoxin and development of hepatocellular carcinoma. The major study objectives were to define a dose and schedule for oltipraz that would reduce levels of aflatoxin biomarkers in biofluids of the participants, and to further characterize dose-limiting side effects. Two hundred thirty-four healthy eligible individuals, including those infected with HBV, were randomized to receive either 125 mg oltipraz daily, 500 mg oltipraz weekly, or placebo. Blood and urine specimens were collected to monitor potential toxicities and evaluate biomarkers over the 8- week intervention and subsequent 8-week follow-up periods. Overall, compliance in the intervention was excellent; approximately 85% of the participants completed the study. Objective evaluation of adverse events was greatly facilitated by inclusion of a placebo arm in the study design. A syndrome involving numbness, tingling, and pain in the fingertips was the only event that occurred more frequently among the active groups (18 and 14% of the daily 125 mg and weekly 500 mg arms, respectively) compared to placebo (3%). These symptoms were reversible and could be relieved with non-steroidal antiinflammatory agents. A more complete understanding of the chemopreventive utility of oltipraz awaits completion of an assessment of the efficacy of oltipraz in modulating levels of aflatoxin biomarkers.

KW - Aflatoxin albumin adducts

KW - Aflatoxin B

KW - Biomarkers

KW - Enzyme induction

KW - Glutathione S-transferases

KW - Hepatocellular carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0031394646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031394646&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 166

EP - 173

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - SUPPL. 28/29

ER -